Takayuki Ueno

List of Publications by Year
in descending order

93 papers	1,376 citations	516215 16 h-index	377514 34 g-index
95 all docs	95 docs citations	95 times ranked	2011 citing authors

#	Article	IF	Citations
1	Trastuzumab and fulvestrant combination therapy for women with advanced breast cancer positive for hormone receptor and human epidermal growth factor receptor 2: a retrospective single-center study. BMC Cancer, 2022, 22, 36.	1.1	4
2	Abstract PD7-05: A multicenter prospective study to predict pathologic complete response by vacuum-assisted breast biopsy based on MRI and US findings after neoadjuvant chemotherapy. Cancer Research, 2022, 82, PD7-05-PD7-05.	0.4	2
3	Abstract P1-15-02: Low incidence of hepatitis B reactivation after chemotherapy in Japanese breast cancer patients with resolved HBV. Cancer Research, 2022, 82, P1-15-02-P1-15-02.	0.4	0
4	Abstract P4-11-06: Effect of suppressed ovarian function on prognosis of premenopausal obese women with hormone receptor-positive breast cancer: A single-institute retrospective study. Cancer Research, 2022, 82, P4-11-06-P4-11-06.	0.4	0
5	Serial circulating tumor DNA monitoring of CDK4/6 inhibitors response in metastatic breast cancer. Cancer Science, 2022, 113, 1808-1820.	1.7	10
6	Assessment of a cancer genomic profile test for patients with metastatic breast cancer. Scientific Reports, 2022, 12, 4813.	1.6	3
7	HER2 expression, copy number variation and survival outcomes in HER2-low non-metastatic breast cancer: an international multicentre cohort study and TCGA-METABRIC analysis. BMC Medicine, 2022, 20, 105.	2.3	60
8	The ELEANOR noncoding RNA expression contributes to cancer dormancy and predicts late recurrence of estrogen receptorâ€positive breast cancer. Cancer Science, 2022, 113, 2336-2351.	1.7	10
9	Immune microenvironment, homologous recombination deficiency, and therapeutic response to neoadjuvant chemotherapy in triple-negative breast cancer: Japan Breast Cancer Research Group (JBCRG)22 TR. BMC Medicine, 2022, 20, 136.	2.3	7
10	Surgical Management of Metastatic Breast Cancer: A Mini Review. Frontiers in Oncology, 2022, 12, .	1.3	3
11	GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. Npj Breast Cancer, 2022, 8, .	2.3	12
12	Pertuzumab retreatment for HER2â€positive advanced breast cancer: A randomized, openâ€label phase III study (PRECIOUS). Cancer Science, 2022, 113, 3169-3179.	1.7	8
13	Ultradeep targeted sequencing of circulating tumor DNA in plasma of early and advanced breast cancer. Cancer Science, 2021, 112, 454-464.	1.7	15
14	Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021. Journal of Hepato-Biliary-Pancreatic Sciences, 2021, 28, 1-25.	1.4	29
15	Utility of Preoperative Computed Tomography Scans for Coronavirus Disease in a Cancer Treatment Center. Cancer Cell, 2021, 39, 9-10.	7.7	6
16	Predictive significance of HER2 intratumoral heterogeneity, determined by simultaneous gene and protein analysis, for resistance to trastuzumab-based treatments for HER2-positive breast cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2021, 479, 13-21.	1.4	4
17	Abstract PS1-19: The accuracy of axillary node assessment of ultrasound after neoadjuvant chemotherapy in clinically node positive patients. , 2021, , .		0
18	Metastatic ovarian cancer spreading into mammary ducts mimicking an in situ component of primary breast cancer: a case report. Journal of Medical Case Reports, 2021, 15, 78.	0.4	6

#	Article	IF	Citations
19	Abstract PS2-32: Incidental malignant findings on pre-admission chest computed tomography scan for coronavirus disease screening in patients with breast cancer or other cancers. , 2021, , .		0
20	Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study. , 2021, , .		1
21	Pathogenicity assessment of variants for breast cancer susceptibility genes based on BRCAness of tumor sample. Cancer Science, 2021, 112, 1310-1319.	1.7	3
22	Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.. Journal of Clinical Oncology, 2021, 39, 1026-1026.	0.8	1
23	Impact of body mass index on the prognosis of Japanese women with operable hormone receptor-positive breast cancer: A single institutional retrospective study.. Journal of Clinical Oncology, 2021, 39, e12547-e12547.	0.8	0
24	Assessment of axillary node status by ultrasound after neoadjuvant chemotherapy in patients with clinically node-positive breast cancer according to breast cancer subtype. Scientific Reports, 2021, 11, 10858.	1.6	5
25	Myofibroblastoma of the breast showing rare palisaded morphology and uncommon desminâ€•and CD34â€•negative immunophenotype: A case report. Pathology International, 2021, 71, 548-555.	0.6	4
26	MO33-7 Preparedness for COVID-19 pandemic and impact on medical oncology for breast cancer. Annals of Oncology, 2021, 32, S320.	0.6	0
27	Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 74-84.	5.1	16
28	Ultrasonographic imaging of invasive ductal carcinoma linked to revision of the histological classification of breast tumors. Choonpa Igaku, 2021, 48, 241-247.	0.0	0
29	Response to Sung, Rosenberg, and Yang. Journal of the National Cancer Institute, 2020, 112, 547-548.	3.0	0
30	Giant cell tumor of soft tissue of the breast: Case report with H3F3A mutation analysis and review of the literature. Pathology Research and Practice, 2020, 216, 152750.	1.0	10
31	Multicenter study of primary systemic therapy with docetaxel, cyclophosphamide and trastuzumab for HER2-positive operable breast cancer: the JBCRG-10 study. Japanese Journal of Clinical Oncology, 2020, 50, 3-11.	0.6	7
32	Efficacy of eribulin for metastatic breast cancer based on localization of specific secondary metastases: a post hoc analysis. Scientific Reports, 2020, 10, 11203.	1.6	6
33	Survival in Cytologically Proven Node-Positive Breast Cancer Patients with Nodal Pathological Complete Response after Neoadjuvant Chemotherapy. Cancers, 2020, 12, 2633.	1.7	1
34	Focused issue â€œNeoadjuvant/adjuvant treatment for early breast cancerâ€• Chinese Clinical Oncology, 2020, 9, 26-26.	0.4	0
35	Breast castleman disease. Breast Journal, 2020, 26, 1855-1856.	0.4	0
36	Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncology, The, 2020, 21, 519-530.	5.1	441

#	Article	IF	Citations
37	Efficacy of radiation boost after breast-conserving surgery for breast cancer with focally positive, tumor-exposed margins. Journal of Radiation Research, 2020, 61, 440-446.	0.8	8
38	Biomarkers of neoadjuvant/adjuvant endocrine therapy for ER-positive/HER2-negative breast cancer. Chinese Clinical Oncology, 2020, 9, 35-35.	0.4	2
39	Local management after neoadjuvant treatment for breast cancer. Chinese Clinical Oncology, 2020, 9, 34-34.	0.4	4
40	Clinical significance of gene mutation in ctDNA analysis for hormone receptor-positive metastatic breast cancer. Breast Cancer Research and Treatment, 2020, 180, 331-341.	1.1	17
41	Abstract OT2-04-07: Phase II study of nivolumab in combination with abemaciclib plus endocrine therapy in patients with hormone receptor-positive, human epidermal growth factor receptor-2 negative metastatic breast cancer (WJOG11418B, NEWFLAME trial). , 2020, , .		3
42	Abstract P5-01-15: Monitoring of CDK4/6 inhibitor treatment response through blood liquid biopsy in metastatic breast cancer. , 2020, , .		0
43	Abstract P5-01-22: Genomic landscape of circulating tumor DNA in early-stage breast cancer. Cancer Research, 2020, 80, P5-01-22-P5-01-22.	0.4	1
44	Estimation of absolute benefit of S-1 postoperative therapy for ER-positive, HER2-negative breast cancer: Exploratory analysis of the phase III potent trial.. Journal of Clinical Oncology, 2020, 38, 532-532.	0.8	0
45	Monitoring of therapeutic efficacy to CDK4/6 inhibitors and early detection of metastatic relapse in breast cancer by ultra-deep sequencing of plasma cell-free DNA.. Journal of Clinical Oncology, 2020, 38, e15544-e15544.	0.8	0
46	International retrospective cohort study of locoregional and systemic therapy in oligometastatic breast cancer (OLIGO-BC1).. Journal of Clinical Oncology, 2020, 38, 1025-1025.	0.8	1
47	Abstract A29: Next-generation sequencing of circulating tumor DNA to monitor treatment response to CDK4/6 inhibitors in breast cancer. , 2020, , .		0
48	A Case of Primary Breast Angiosarcoma in a 20-year-old Woman. Nihon Rinsho Geka Gakkai Zasshi (Journal of Japan Surgical Association), 2020, 81, 2432-2436.	0.0	0
49	Abstract GS1-09: Addition of S-1 to endocrine therapy in the post-operative adjuvant treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative primary breast cancer: A multicenter, open-label, phase 3 randomized trial (POTENT trial). , 2020, , .		1
50	Clinicopathological features of breast cancer patients with internal mammary and/or supraclavicular lymph node recurrence without distant metastasis. BMC Cancer, 2020, 20, 932.	1.1	4
51	Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12Âweeks' exemestane exposure in patients with estrogen receptorâ€positive breast cancer: A multicenter, openâ€label, phase II study. Cancer Medicine, 2019, 8, 5468-5481.	1.3	4
52	Treating HR+/HER2â^' breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. Breast Cancer Research and Treatment, 2019, 177, 549-559.	1.1	29
53	Altered lymphatic drainage patterns in re-operative sentinel lymph node biopsy for ipsilateral breast tumor recurrence. Radiation Oncology, 2019, 14, 159.	1.2	11
54	Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population. Journal of the National Cancer Institute, 2019, 111, 1298-1306.	3.0	83

#	Article	IF	Citations
55	Differential Involvement of Autophagy and Apoptosis in Response to Chemoendocrine and Endocrine Therapy in Breast Cancer: JBCRG-07TR. International Journal of Molecular Sciences, 2019, 20, 984.	1.8	16
56	Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial. Clinical Cancer Research, 2019, 25, 3581-3588.	3.2	73
57	Changes in Recurrence Score by neoadjuvant endocrine therapy of breast cancer and their prognostic implication. ESMO Open, 2019, 4, e000476.	2.0	17
58	Characteristics and prognosis of leptomeningeal metastasis in patients with breast cancer. Annals of Oncology, 2019, 30, vi113.	0.6	0
59	Prognostic impact and possible pathogenesis of lymph node metastasis in ductal carcinoma in situ of the breast. Breast Cancer Research and Treatment, 2019, 174, 103-111.	1.1	7
60	Risk Factors for Skin Flap Necrosis in Breast Cancer Patients Treated with Mastectomy Followed by Immediate Breast Reconstruction. World Journal of Surgery, 2019, 43, 846-852.	0.8	24
61	Impact of clinical response to neoadjuvant endocrine therapy on patient outcomes: a follow-up study of JFMC34-0601 multicentre prospective neoadjuvant endocrine trial. ESMO Open, 2018, 3, e000314.	2.0	15
62	Progesterone receptor expression in proliferating cancer cells of hormone-receptor-positive breast cancer. Tumor Biology, 2018, 40, 101042831881102.	0.8	5
63	Only a few young patients aged 40 years with â€˜high-riskâ€™ breast cancer preserved fertility; report from actual survey in a Japanese cancer hospital. Breast, 2018, 41, S26-S27.	0.9	0
64	A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study. Japanese Journal of Clinical Oncology, 2018, 48, 855-859.	0.6	6
65	A multicenter phase II trial of neoadjuvant letrozole plus lowâ€dose cyclophosphamide in postmenopausal patients with estrogen receptorâ€positive breast cancer (JBCRGâ€07): therapeutic efficacy and clinical implications of circulating endothelial cells. Cancer Medicine, 2018, 7, 2442-2451.	1.3	10
66	Neoadjuvant endocrine therapy with exemestane followed by response-guided combination therapy with low-dose cyclophosphamide in postmenopausal patients with estrogen receptor-positive breast cancer: A multicenter, open-label, phase II study. Cancer Medicine, 2018, 7, 3044-3056.	1.3	10
67	Differences of TILs, hormone receptor, and HER2 status between primary and metastatic tumors.. Journal of Clinical Oncology, 2018, 36, 1075-1075.	0.8	1
68	The lack of increases in circulating endothelial progenitor cell as a negative predictor for pathological response to neoadjuvant chemotherapy in breast cancer patients. Npj Precision Oncology, 2017, 1, 6.	2.3	13
69	A phase I/<scp>II</scp> pharmacokinetics/pharmacodynamics study of irinotecan combined with Sâ^'1 for recurrent/metastatic breast cancer in patients with selected <scp>UGT</scp>1A1 genotypes (the) Tj ETQq1 1 0.784314 rgBT /O		
70	Trends in axillary treatment for breast cancer patients undergoing sentinel lymph node biopsy as determined by a questionnaire from the Japanese Breast Cancer Society. Breast Cancer, 2017, 24, 427-432.	1.3	3
71	Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components.. Journal of Clinical Oncology, 2017, 35, e12094-e12094.	0.8	1
72	Clinical significance of the expression of autophagy-associated marker, beclin 1, in breast cancer patients who received neoadjuvant endocrine therapy. BMC Cancer, 2016, 16, 230.	1.1	30

#	Article	IF	Citations
73	PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.. Journal of Clinical Oncology, 2016, 34, TPS636-TPS636.	0.8	0
74	Phase II study on radiofrequency ablation in early breast cancer.. Journal of Clinical Oncology, 2016, 34, e12536-e12536.	0.8	0
75	Abstract 4138: Immunological profile of metastatic or recurrent breast cancer patients. , 2016, , .		0
76	Abstract 3484: Analysis ofin situexpression of hormone receptors and proliferation marker at a single cell level in breast cancer tissues. , 2016, , .		0
77	Characteristic Gene Expression Profiles of Human Fibroblasts and Breast Cancer Cells in a Newly Developed Bilateral Coculture System. BioMed Research International, 2015, 2015, 1-11.	0.9	16
78	PO130 CLINICAL UTILITY OF THE EXPRESSION OF HER3, HER4, PTEN AND IGF1R IN HER2-POSITIVE ADVANCED OR METASTATIC BREAST CANCER. Breast, 2015, 24, S66.	0.9	0
79	Abstract OT1-3-01: Phase II study on radiofrequency ablation in stage 0 and I breast cancer without extensive intraductal components. , 2015, , .		0
80	Evaluating the 21-gene assay Recurrence ScoreÂ® as a predictor of clinical response to 24Âweeks of neoadjuvant exemestane in estrogen receptor-positive breast cancer. International Journal of Clinical Oncology, 2014, 19, 607-613.	1.0	54
81	Comment and reply on: Vasohibin-1 and its emerging role in the evolution and progression of systemic tumors besides renal cell carcinomas. Expert Opinion on Therapeutic Targets, 2013, 17, 105-106.	1.5	1
82	Interobserver concordance of <scp>K</scp>i67 labeling index in breast cancer: <scp>J</scp>apan <scp>B</scp>reast <scp>C</scp>ancer <scp>R</scp>esearch <scp>G</scp>roup <scp>K</scp>i67 <scp>R</scp>ing <scp>S</scp>tudy. Cancer Science, 2013, 104, 1539-1543.	1.7	65
83	Breast MR Image Fusion by Deformable Implicit Polynomial (DIP). IPSJ Transactions on Computer Vision and Applications, 2013, 5, 99-103.	4.4	3
84	Relationship of tumor and stromal autophagy and endocrine responsiveness in breast cancer tissues.. Journal of Clinical Oncology, 2013, 31, 571-571.	0.8	0
85	Genome-wide copy number analysis in primary breast cancer. Expert Opinion on Therapeutic Targets, 2012, 16, S31-S35.	1.5	22
86	Relationship between body mass index and preoperative treatment response to aromatase inhibitor exemestane in postmenopausal patients with primary breast cancer. Breast, 2012, 21, 40-45.	0.9	14
87	Determining circulating endothelial cells using CellSearch system during preoperative systemic chemotherapy in breast cancer patients. European Journal of Cancer, 2011, 47, 2265-2272.	1.3	27
88	Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24â€ƒweeks of aromatase inhibition. Cancer Science, 2011, 102, 858-865.	1.7	44
89	Serial measurement of serum S-100B protein as a marker of cerebral damage after cardiac surgery. Annals of Thoracic Surgery, 2003, 75, 1892-1897.	0.7	28
90	Penetrating Atherosclerotic Ulcer. Surgery Today, 2001, 31, 32-35.	0.7	20

#	Article	IF	Citations
91	Primary mediastinal germ cell tumor with absent elevation of AFP at recurrence; a case report.. The Journal of the Japanese Association for Chest Surgery, 1997, 11, 186-193.	0.0	0
92	Utility of Repeat Sentinel Lymph Node Biopsy for cN0 Ipsilateral Breast Tumor Recurrence in Patients Initially Treated with Breast-Conserving Surgery and Sentinel Lymph Node Biopsy. SSRN Electronic Journal, 0, , .	0.4	0
93	Characteristics, treatment trends, and long-term outcomes of Japanese patients with pregnancy-associated breast cancer (PABC). Breast Cancer, 0, , .	1.3	1